At AstraZeneca, we’re continuing to better understand the important role of eosinophils as key effector cells in a range of potentially devasting inflammatory diseases, in which elevated eosinophils are a direct cause or are thought to play a critical role. We know now that a process called eosinophilic immune dysfunction may be responsible for the eosinophil recruitment and activation that is driving these diseases. Backed by a growing body of evidence, we’re committed to advancing the understanding of the role of eosinophils in inflammatory diseases, with the aim to improve diagnosis, patient referrals and timely, appropriate treatment.